MorandEFFurieRTanakaY, et al.
Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med2020;
382: 211–221.
4.
FurieRAMorandEFBruceIF, et al.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol2019;
1: e208–e219.
5.
US Food and Drug Administration. Guidance for industry: systemic lupus erythematosus – developing medical products for treatment by CDER, CBER and CDRH, https://www.fda.gov/media/71150/download (accessed 5 February 2020).
6.
AltmanDGMoherDSchulzKF.Harms of outcome switching in reports of randomised trials: CONSORT perspective. BMJ2017;
356: j396.
